MedTrace Logo

A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Midazolam in the Blood

NCT05550636 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-12-01

Study results available
· View outcomes & findings →

Summary

The main objective of this trial is to investigate the induction effect of multiple doses of BI 1015550 on the pharmacokinetics of the sensitive CYP3A4 substrate midazolam.

Conditions

  • Healthy

Interventions

DRUG

BI 1015550

BI 1015550

DRUG

midazolam

midazolam

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-11
Primary Completion
2022-12-19
Completion
2022-12-19

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05550636 on ClinicalTrials.gov